Hope Rugo
University of California, San Francisco
H-index: 130
North America-United States
Top articles of Hope Rugo
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Abstract PO4-19-06: Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue … | Cancer Research | Neelima Vidula Senthil Damodaran Manali Bhave Hope Rugo Ami N Shah | 2024/5/2 |
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative) | Hope S Rugo Aditya Bardia Frederik Marmé Javier Cortés Peter Schmid | 2024/1 | |
Abstract B077: Subtype-specific signaling dynamics during treatment in non-responding breast cancer patients in the neoadjuvant I-SPY2 TRIAL: are there clues on how to overcome … | Cancer Research | Denise M Wolf Christina Yau Mark Jesus M Magbanua Rosalyn Sayaman Julia Wulfkhule | 2024/2/1 |
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2–breast cancer | Aditya Bardia Komal Jhaveri Kevin Kalinsky Sonia Pernas Junji Tsurutani | 2024/3 | |
Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2-metastatic breast cancer (mBC): the … | Cancer Research | Senthil Damodaran Massimo Cristofanilli Matthew Goetz Ciara O'Sullivan Gary Riordan | 2024/5/2 |
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy | Clinical Cancer Research | Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown Swigart Gillian L Hirst | 2024/4/10 |
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. | Journal of Clinical Oncology | Nadia Harbeck Seock-Ah Im Karen Gelmon Oleg Lipatov Janice Walshe | 2024/3/20 |
Abstract RF02-06: AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N)+ trastuzumab (H) alone or combined with avelumab (A)+/-utomilumab (U) in patients (pts) with … | Cancer Research | Adrienne Waks Ruichao Shi Meredith Regan Chau Dang Cesar Santa-Maria | 2024/5/2 |
68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG | Journal of Nuclear Medicine | Brad Kline Surekha Yadav Youngho Seo Robin Cumming Ippisch Jessa Castillo | 2024/5/2 |
Abstract PS17-03: Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by … | Cancer Research | Sacha Howell Hope Rugo Mafalda Oliveira Florence Dalenc Javier Cortés | 2024/5/2 |
Abstract PO2-19-08: INAVO121: Phase III study of inavolisib+ fulvestrant vs alpelisib+ fulvestrant in patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated … | Cancer Research | Dejan Juric Kevin Kalinsky Seock-Ah Im Eva Ciruelos Giampaolo Bianchini | 2024/5/2 |
Abstract PO2-19-10: CAPItello-292 Phase 3: An open-label, randomized study of capivasertib, fulvestrant, and investigator’s choice of CDK4/6 inhibitor (palbociclib or … | Cancer Research | Hope Rugo Barbara Pistilli Julie Collins Celina D’Cruz Christopher Gresty | 2024/5/2 |
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline | JCO global oncology | Sana Al Sukhun Sarah Temin Carlos H Barrios Nicoleta Zenovia Antone Yanin Chavarri Guerra | 2024/1 |
Abstract A014: Cell-free DNA concentration as a biomarker of response and recurrence in HER-2 negative breast cancer receiving neoadjuvant chemotherapy | Cancer Research | Mark Jesus M Magbanua Ziad Ahmed Rosalyn W Sayaman Lamorna Brown-Swigart Gillian L Hirst | 2024/2/1 |
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor … | Journal of Clinical Oncology | Aditya Bardia Hope S Rugo Sara M Tolaney Delphine Loirat Kevin Punie | 2024/2/29 |
Abstract PS02-02: Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR … | Cancer Research | Hope Rugo Mafalda Oliveira Sacha Howell Florence Dalenc Javier Cortés | 2024/5/2 |
Abstract PO1-05-09: ASCENT-07: A phase 3, randomized, open-label study of sacituzumab govitecan versus treatment of physician’s choice in patients with HR+/HER2–inoperable … | Cancer Research | Hope Rugo Javier Cortés Giuseppe Curigliano Carlos Barrios Kevin Punie | 2024/5/2 |
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary | Adam Brufsky Xianchen Liu Benjamin Li Lynn McRoy Connie Chen | 2024/3 | |
Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final … | Cancer Research | Antonio Giordano Nisha Unni Senthil Damodaran Hope Rugo Timothy Crook | 2024/5/2 |
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer | Journal of clinical oncology: official journal of the American Society of Clinical Oncology | Alejandro Ríos-Hoyo Erin Cobain Laura A Huppert Peter D Beitsch Thomas A Buchholz | 2024/4/9 |
